All-cash deal: Gilead Sciences buys Israeli firm for nearly $12B ‎‎‎

Posted August 31, 2017

The firm has "Buy" rating by Gabelli given on Wednesday, June 1. Finally, Raymond James Financial, Inc. reissued a mkt perform rating on shares of Kite Pharma in a report on Monday, May 8th. (NASDAQ:KITE) from a buy rating to a neutral rating in a research report report published on Monday. Morgan Stanley maintained it with "Equal-Weight" rating and $103 target in Thursday, May 26 report. The stock has "Buy" rating by Mizuho on Tuesday, May 10.

Spartacus Star Andy Whitfield a Year Before His Death from Non Hodgkin Lymphoma
Spartacus Blood and Sand Actor Andy Whitfield in 2010

Schroer said he was "very comfortable" that Kite had the ability to meet its goals for the axi-cel launch and then expand use of the treatment to less sick patients or those with other diseases. It took the plunge by announcing it would acquire Kite Pharma Inc. DOUMANI ROY had sold 15,000 shares worth $1.27 million on Wednesday, June 7. Capital Rech Global Invsts reported 24.77M shares. With 803,100 avg volume, 4 days are for Medidata Solutions Incorporated (NASDAQ:MDSO)'s short sellers to cover MDSO's short positions. The SI to Mattersight Corporation's float is 4.74%. These shares are worth $1,810,800 and were traded at $120.72 each. (NASDAQ:GILD). Brown Management Ltd Liability has invested 0.02% in Gilead Sciences, Inc.

More news: Nigeria vs Cameroon: Rohr happy to have "full house"

Investors sentiment increased to 0.93 in 2016 Q4. It dropped, as 34 investors sold Kite Pharma Inc shares while 43 reduced holdings. It also upped Allstate Corp (NYSE:ALL) stake by 10,055 shares and now owns 63,045 shares. The stock rose 0.73% or $1.24 reaching $170.98. Hall Laurie J Trustee has 60 shares for 0% of their portfolio. Suntrust Banks reported 0.12% of its portfolio in Gilead Sciences, Inc. Axiom Int Invsts De holds 35,086 shares. Metropolitan Life Ny holds 27,967 shares. Peak Asset Mgmt Ltd Llc has invested 1.53% of its portfolio in Gilead Sciences, Inc. Us Bank De holds 14,025 shares or 0% of its portfolio. Thompson Siegel Walmsley Limited Liability Corporation reported 139,122 shares stake. Sentinel Asset Mngmt owns 210,400 shares or 0.77% of their U.S. portfolio. Gilead Sciences Inc Com now has $96.36B valuation. It has a 40.14 P/E ratio. The company develops biotech therapies and treatments, not pills. BUTITTA CYNTHIA M also sold $2.86M worth of Kite Pharma Inc (NASDAQ:KITE) shares. The insider TAYLOR ROBERT sold $414,241. The stock of Kite Pharma Inc (NASDAQ:KITE) earned "Buy" rating by Stifel Nicolaus on Sunday, August 16. Afam accumulated 59,446 shares or 0.64% of the stock. The firm has "Hold" rating by Maxim Group given on Friday, April 29. The company was maintained on Friday, November 13 by FBR Capital. But Gilead stock was less enthusiastic, rising 2.3%, near 75.50. Can now owns 5,013 shares of the biopharmaceutical company's stock worth $392,000 after buying an additional 1,100 shares during the last quarter. The rating was initiated by Jefferies on Wednesday, September 9 with "Hold".

More news: Hezbollah leader defends evacuation of IS fighters

The Wall Street Journal first reported the deal on Monday. Parametric Portfolio Associates Llc holds 0% or 18,377 shares. GILD shares gained over 1.2% while KITE shares surged about 28% on the day, responding to the super deal. In a transaction dated August 08, 2017, the shares were put up for sale at an average price of $119.56, raking in a sum of $9,558,702. It was founded in 2009 by Israeli-American oncologist Arie Belldegrun, who is today its chairman, president and CEO. Shares for $97,300 were bought by Ruchefsky Steven B on Tuesday, May 9.

More news: Gas Prices Hit 2 Year High as 'Harvey' Disrupts Gulf Coast Refineries

Kite Pharma (NASDAQ:KITE) last released its quarterly earnings data on Tuesday, August 8th. It has underperformed by 38.50% the S&P500. Its down 0.23, from 0.93 in 2016Q3. Of those insider trades, 525 shares of Gilead Sciences, Inc. were purchased and 286,272 shares were sold. 30 funds opened positions while 71 raised stakes. Alps Advsr holds 0.02% or 47,930 shares. FBR & Co restated an "outperform" rating and issued a $91.00 price objective (up previously from $90.00) on shares of Kite Pharma in a research report on Tuesday, May 9th. Nbt Bancorp N A reported 0.17% in Gilead Sciences, Inc.